Tyra Biosciences, Inc.
TYRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 46.8% and free cash flow fell 31.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TYRA
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Net Income |
(119.95) | (86.48) | (69.13) | (55.32) | (26.29) | (9.34) | (4.06) | 0.00 |
Depreciation & Amortization |
0.55 | 0.52 | 0.36 | 0.30 | 0.14 | 0.05 | 0.01 | — |
Non Cash Items (Other) |
25.89 | 16.92 | 12.28 | 10.59 | 2.89 | 0.46 | — | — |
Change in payables and accrued liability |
3.37 | (0.74) | 9.37 | 2.36 | 1.49 | 1.02 | — | — |
Change in other assets and liabilities |
(5.00) | 0.02 | (3.01) | (8.20) | (1.97) | 0.05 | 0.51 | — |
Other operating activities |
— | — | — | — | — | — | — | 0.00 |
Operating Cash Flow |
(95.14) | (69.77) | (50.14) | (50.28) | (23.74) | (7.76) | (2.62) | — |
Capital expenditures |
(0.14) | (0.66) | (0.77) | (0.56) | (0.64) | (0.31) | — | — |
Short Term Investments Change (Net) |
72.60 | (97.74) | (143.83) | — | — | — | — | — |
Investing cash flow |
72.46 | (98.40) | (144.60) | (0.56) | (0.64) | (0.31) | (0.02) | — |
Repayment/Issuance of Debt (Net) |
— | — | — | — | (0.01) | (0.02) | (0.01) | — |
Equity Repurchase (Common, Net) |
8.10 | 202.56 | 1.54 | 0.63 | 181.73 | 0.14 | — | — |
Equity Repurchase (Preffered, Net) |
— | — | — | — | 129.62 | 23.31 | — | — |
Other financial activities |
— | (0.42) | — | 10.59 | 2.87 | 0.46 | 0.93 | — |
Financing cash flow |
8.10 | 202.14 | 1.54 | 0.63 | 311.35 | 23.43 | 0.16 | — |
Change in Cash |
(14.58) | 33.96 | (193.21) | (50.21) | 286.96 | 15.36 | (2.48) | — |
Beginning Cash |
92.97 | 59.01 | 252.21 | 302.43 | 15.47 | 0.11 | — | — |
Ending Cash |
78.39 | 92.97 | 59.01 | 252.21 | 302.43 | 15.47 | — | — |
Stock Based Compensation |
28.01 | 22.80 | 13.53 | 10.59 | 2.89 | 0.44 | — | — |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Assets Liabilities Change (Total) |
(1.63) | (0.73) | 6.36 | (5.85) | (0.48) | 1.07 | — | — |
Investments Change (Net) |
72.60 | (97.74) | (143.83) | — | — | — | — | — |
Issuance/Purchase of Shares |
8.10 | 202.56 | 1.54 | 0.63 | 311.36 | 23.45 | — | — |
| Other line items | ||||||||
Revenue per Employee |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |